https://www.selleckchem.com/products/iox1.html
Patients enrolled in Phase 1 clinical trials have typically exhausted standard therapies and often are choosing between a clinical trial and hospice care. Significant symptom burden can result in early trial discontinuation and confound trial outcomes. This study aimed to examine differences in study duration, symptom burden, adverse events (AE), and quality of life (QOL) between those receiving structured palliative care versus usual supportive care. Sixty-eight patients enrolled in phase 1 clinical trials and 39 of their CGs were randoml
Like
Comment
Share
